Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Construction in Progress Convertible Debt Current Assets Current Deferred Revenue Current Leases Finished Goods Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Liabilities from Discontinued Operations Long-Term Deferred Tax Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Others

Neuroone Medical Technologies (NMTC) Notes Payables (2016 - 2024)

Neuroone Medical Technologies filings provide 10 years of Notes Payables readings, the most recent being $121896.0 for Q1 2024.

On a quarterly basis, Notes Payables changed N/A to $121896.0 in Q1 2024 year-over-year; TTM through Mar 2024 was $121896.0, a N/A change, with the full-year FY2023 number at $129116.0, changed N/A from a year prior.
Notes Payables hit $121896.0 in Q1 2024 for Neuroone Medical Technologies, down from $129116.0 in the prior quarter.
In the past five years, Notes Payables ranged from a high of $1.0 million in Q3 2020 to a low of $121896.0 in Q1 2024.
Median Notes Payables over the past 3 years was $129116.0 (2023), compared with a mean of $419406.0.